<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01830543</url>
  </required_header>
  <id_info>
    <org_study_id>CR100758</org_study_id>
    <secondary_id>RIVAROXAFL3003</secondary_id>
    <secondary_id>2012-001491-11</secondary_id>
    <nct_id>NCT01830543</nct_id>
  </id_info>
  <brief_title>A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention</brief_title>
  <acronym>PIONEER AF-PCI</acronym>
  <official_title>An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Janssen Scientific Affairs, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety for 2 different rivaroxaban
      treatment strategies and one Vitamin K Antagonist (VKA) treatment strategy utilizing various
      combinations of dual antiplatelet therapy (DAPT) or low-dose aspirin (ASA) or clopidogrel (or
      prasugrel or ticagrelor).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label (both physician and participant know the treatment that the participant
      receives), randomized (study medication is assigned by chance), multicenter clinical study
      assessing the safety of 2 rivaroxaban treatment strategies and one vitamin K antagonist (VKA)
      treatment strategy in participants, who have paroxysmal, persistent, or permanent
      non-valvular atrial fibrillation (AF) and have had a percutaneous coronary intervention (PCI)
      with stent placement.

      A target of 2,100 participants will be randomized into the study, with approximately 700
      participants in each treatment strategy group. The randomization will be stratified by the
      intended duration of DAPT (1, 6, or 12 months).

      The study consists of a screening phase, a 12-month open-label treatment phase, and an
      end-of-treatment/early withdrawal visit. The total duration of participation in the study for
      each participant is approximately 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2013</start_date>
  <completion_date type="Actual">July 28, 2016</completion_date>
  <primary_completion_date type="Actual">July 28, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Clinically Significant Bleeding</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>Clinically significant bleeding is a composite of Thrombolysis in Myocardial Infarction (TIMI) major bleeding, minor bleeding, and bleeding requiring medical attention (BRMA). TIMI major bleeding is defined as any symptomatic intracranial hemorrhage, clinically overt signs of hemorrhage (including imaging) associated with a drop in hemoglobin of greater than or equal to (&gt;=) 5 grams per deciliter (g/dL) (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of &gt;=15 percent (%)). TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to less than (&lt;) 5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to &lt;15 percent). A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding</measure>
    <time_frame>Up to Month 12 and end of DAPT-Month 1, 6 and 12</time_frame>
    <description>TIMI major bleeding is defined as any symptomatic intracranial hemorrhage, Clinically overt signs of hemorrhage (including imaging) associated with a drop in hemoglobin of &gt;= 5 g/dL (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of &gt;=15 percent).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Minor Bleeding</measure>
    <time_frame>Up to Month 12 and end of DAPT-Month 1, 6 and 12</time_frame>
    <description>TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to &lt;5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to &lt;15 percent).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Bleeding Requiring Medical Attention (BRMA)</measure>
    <time_frame>Up to Month 12 and end of DAPT-Month 1, 6 and 12</time_frame>
    <description>A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Composite of Adverse Cardiovascular Events (Cardiovascular Death, Myocardial Infarction (MI) and Stroke)</measure>
    <time_frame>Up to Month 12 and end of DAPT-Month 1, 6 and 12</time_frame>
    <description>Percentage of participants who experienced adverse cardiovascular events (cardiovascular death, myocardial Infarction (MI) and stroke) collectively, were assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Cardiovascular Death</measure>
    <time_frame>Up to Month 12 and end of DAPT-Month 1, 6 and 12</time_frame>
    <description>The percentage of participants with the first occurrence of cardiovascular death were evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Myocardial Infarction</measure>
    <time_frame>Up to Month 12 and end of DAPT-Month 1, 6 and 12</time_frame>
    <description>The percentage of participants with the first occurrence of Myocardial Infarction were evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Stroke</measure>
    <time_frame>Up to Month 12 and end of DAPT-Month 1, 6 and 12</time_frame>
    <description>The percentage of participants with the first occurrence of Stroke were evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Stent Thrombosis</measure>
    <time_frame>Up to Month 12 and end of DAPT-Month 1, 6 and 12</time_frame>
    <description>The percentage of participants with the first occurrence of stent thrombosis were evaluated.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2124</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>rivaroxaban 2.5 mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rivaroxaban 2.5 mg tablet twice daily plus low-dose aspirin (ASA) 75 to 100 mg once daily and clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by rivaroxaban 15 mg tablet (or 10 mg for subjects with moderate renal impairment) once daily plus low-dose ASA for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamin K antagonist (VKA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose-adjusted vitamin K antagonist (VKA) once daily (target International Normalized Ratio (INR) 2.0 to 3.0) plus low-dose ASA, 75 to 100 mg per day, and clopidogrel 75 mg once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by dose-adjusted VKA once daily (target INR 2.0 to 3.0 or 2.0 to 2.5 at the investigator discretion) plus low-dose ASA for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rivaroxaban 15 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivaroxaban 2.5 mg</intervention_name>
    <description>One 2.5 mg tablet twice daily for up to twelve months</description>
    <arm_group_label>rivaroxaban 2.5 mg twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivaroxaban 15 mg</intervention_name>
    <description>One 15 mg tablet once daily for up to twelve months</description>
    <arm_group_label>rivaroxaban 2.5 mg twice daily</arm_group_label>
    <arm_group_label>rivaroxaban 15 mg once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivaroxaban 10 mg</intervention_name>
    <description>One 10 mg tablet once daily for up to twelve months</description>
    <arm_group_label>rivaroxaban 2.5 mg twice daily</arm_group_label>
    <arm_group_label>rivaroxaban 15 mg once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin (ASA)</intervention_name>
    <description>Low-dose aspirin tablet once daily for twelve months</description>
    <arm_group_label>rivaroxaban 2.5 mg twice daily</arm_group_label>
    <arm_group_label>vitamin K antagonist (VKA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin K antagonist (VKA)</intervention_name>
    <description>Dose-adjusted VKA tablet (target International Normalized Ratio (INR) 2.0 to 3.0) once daily for twelve months</description>
    <arm_group_label>vitamin K antagonist (VKA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>One 75 mg tablet once daily for up to twelve months</description>
    <arm_group_label>rivaroxaban 2.5 mg twice daily</arm_group_label>
    <arm_group_label>vitamin K antagonist (VKA)</arm_group_label>
    <arm_group_label>rivaroxaban 15 mg once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prasugrel</intervention_name>
    <description>One 10 mg tablet once daily for up to twelve months</description>
    <arm_group_label>rivaroxaban 2.5 mg twice daily</arm_group_label>
    <arm_group_label>vitamin K antagonist (VKA)</arm_group_label>
    <arm_group_label>rivaroxaban 15 mg once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ticagrelor</intervention_name>
    <description>One 90 mg tablet twice daily for up to twelve months</description>
    <arm_group_label>rivaroxaban 2.5 mg twice daily</arm_group_label>
    <arm_group_label>vitamin K antagonist (VKA)</arm_group_label>
    <arm_group_label>rivaroxaban 15 mg once daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a documented medical history of paroxysmal, persistent, or permanent non-valvular
             atrial fibrillation (AF)

          -  Have undergone percutaneous coronary intervention (PCI) procedure (with stent
             placement) for primary atherosclerotic disease

          -  Must have an international normalized ratio (INR) of 2.5 or below to be randomized

          -  Women must be postmenopausal before entry or practicing a highly effective method of
             birth control when heterosexually active

          -  Be willing and able to adhere to the prohibitions and restrictions specified in the
             study protocol

        Exclusion Criteria:

          -  Have any condition that contraindicates anticoagulant or antiplatelet therapy or would
             have an unacceptable risk of bleeding, such as, but not limited to: platelet count
             &lt;90,000/microliter at screening, history of intracranial hemorrhage, 12 month history
             of clinically significant gastrointestinal bleeding, non-VKA induced elevated
             prothrombin time (PT) at screening

          -  Have anemia of unknown cause with a hemoglobin level &lt;10 g/dL (&lt;6.21 mmol/L)

          -  Have a history of stroke or Transient Ischemic Attack (TIA)

          -  Have a calculated Creatinine Clearance (CrCl) &lt;30 mL/min at screening

          -  Have known significant liver disease or liver function test (LFT) abnormalities

          -  Have any severe condition that would limit life expectancy to less than 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Scientific Affairs, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Scientific Affairs, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Safety Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hazel Crest</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hammond</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mount Clemens</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haddon Heights</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peekskill</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sanford</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bartlesville</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Humble</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Weston</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bahia Blanca</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>C.a.b.a.</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corrientes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Resistencia</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vicente Lopez</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chermside N/A</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Epping</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hobart</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kogarah</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Lambton</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wollongong</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasschaat</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mechelen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mol</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Blumenau</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasilia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campina Grande Do Sul</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marilia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Passo Fundo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Recife</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São José Do Rio Preto</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uberlandia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Votuporanga</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Blagoevgrad</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burgas</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pazardjik</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Veliko Tarnovo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maple Ridge</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. John'S</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicoutimi</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint John</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alto</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concepcion</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Punta Arenas</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno 2</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradec Kralove</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jablonec Na Nisou</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karlovy Vary</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kladno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Litomysl</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plzen</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 10 N/A</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 2</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Slany</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uherske Hradiste</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Esbjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herning</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koege</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naestved</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Svendborg N/A</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Besancon Cedex Franche-Comté</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Centres</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chartres</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Limoges Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille Cedex 05</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montfermeil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris 75</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pau</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Friedrichshall</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Esslingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt Am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Limburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyeonggi-Do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uijeongbu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Georgetown</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johor Bahru</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kajang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leon</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pachuca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Puebla</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Queretaro</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villahermosa</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zapopan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam Zuidoost</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gorinchem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sneek</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bedzin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bielsko-Biala</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chrzanow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mielec</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nowy Targ</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrowiec Swietokrzyski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oswiecim</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plock</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rzeszow Poland</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Starachowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Starogard Gdanski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tychy</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ustron</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zamosc</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Targu-Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tg Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chita</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perm</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rostov On Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Syktyvkar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Centurion</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linksfield West, Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Somerset West</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Falun</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jönköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm N/A</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gaziantep</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul Nap</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kayseri</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sivas</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cherkassy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Khemelnitskiy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rivne</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uzhgorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Blackburn</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clydebank</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dorchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hampshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harrow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>High Wycombe</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Middlesbrough N/A</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portsmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torquay</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Truro</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>April 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2013</study_first_posted>
  <results_first_submitted>June 30, 2017</results_first_submitted>
  <results_first_submitted_qc>June 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2017</results_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Irregular heart beat</keyword>
  <keyword>rivaroxaban</keyword>
  <keyword>aspirin</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>prasugrel</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>vitamin K antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rivaroxaban 15 mg</title>
          <description>Participants received rivaroxaban 15 milligram (mg) or 10 mg (for participants with moderate renal impairment [creatinine clearance (CrCl): 30 to less than (&lt;) 50 milliliter per minute (mL/min)]) once daily plus background therapy with clopidogrel 75 mg once daily or alternate P2Y12 inhibitor (prasugrel 10 mg per day or ticagrelor 90 mg twice daily) for 12 months.</description>
        </group>
        <group group_id="P2">
          <title>Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)</title>
          <description>Participants received rivaroxaban 2.5 mg twice daily plus background dual antiplatelet therapy (DAPT) with low-dose acetylsalicylic acid (ASA) 75 to 100 mg per day and clopidogrel 75 mg once daily (or alternate P2Y12 inhibitor [prasugrel or ticagrelor]) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive rivaroxaban 15 mg or 10 mg (for participants with moderate renal impairment) once daily plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
        </group>
        <group group_id="P3">
          <title>Vitamin K Antagonist (VKA)</title>
          <description>Participants received dose adjusted (to a target of international normalized ratio [INR] 2.0 to 3.0 [or target INR 2.0 to 2.5]) vitamin K antagonist (VKA) [example warfarin, acenocoumarol; assigned by the investigator according to approved formulations) once daily plus background DAPT (clopidogrel 75 mg [or alternate P2Y12 inhibitor (prasugrel or ticagrelor)] plus low-dose ASA [75 to 100 mg] daily) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive dose-adjusted VKA plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="709"/>
                <participants group_id="P2" count="709"/>
                <participants group_id="P3" count="706"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="696"/>
                <participants group_id="P2" count="706"/>
                <participants group_id="P3" count="697"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="550"/>
                <participants group_id="P2" count="557"/>
                <participants group_id="P3" count="492"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
                <participants group_id="P2" count="152"/>
                <participants group_id="P3" count="214"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject Decision</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="57"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="76"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by consent</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The intent-to-treat analysis set included all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Rivaroxaban 15 mg</title>
          <description>Participants received rivaroxaban 15 milligram (mg) or 10 mg (for participants with moderate renal impairment [creatinine clearance (CrCl): 30 to less than (&lt;) 50 milliliter per minute (mL/min)]) once daily plus background therapy with clopidogrel 75 mg once daily or alternate P2Y12 inhibitor (prasugrel 10 mg per day or ticagrelor 90 mg twice daily) for 12 months.</description>
        </group>
        <group group_id="B2">
          <title>Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)</title>
          <description>Participants received rivaroxaban 2.5 mg twice daily plus background dual antiplatelet therapy (DAPT) with low-dose acetylsalicylic acid (ASA) 75 to 100 mg per day and clopidogrel 75 mg once daily (or alternate P2Y12 inhibitor [prasugrel or ticagrelor]) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive rivaroxaban 15 mg or 10 mg (for participants with moderate renal impairment) once daily plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
        </group>
        <group group_id="B3">
          <title>Vitamin K Antagonist (VKA)</title>
          <description>Participants received dose adjusted (to a target of international normalized ratio [INR] 2.0 to 3.0 [or target INR 2.0 to 2.5]) vitamin K antagonist (VKA) [example warfarin, acenocoumarol; assigned by the investigator according to approved formulations) once daily plus background DAPT (clopidogrel 75 mg [or alternate P2Y12 inhibitor (prasugrel or ticagrelor)] plus low-dose ASA [75 to 100 mg] daily) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive dose-adjusted VKA plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="709"/>
            <count group_id="B2" value="709"/>
            <count group_id="B3" value="706"/>
            <count group_id="B4" value="2124"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.4" spread="9.12"/>
                    <measurement group_id="B2" value="70" spread="9.11"/>
                    <measurement group_id="B3" value="69.9" spread="8.67"/>
                    <measurement group_id="B4" value="70.1" spread="8.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="188"/>
                    <measurement group_id="B4" value="543"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="528"/>
                    <measurement group_id="B2" value="535"/>
                    <measurement group_id="B3" value="518"/>
                    <measurement group_id="B4" value="1581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan, Province of China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Clinically Significant Bleeding</title>
        <description>Clinically significant bleeding is a composite of Thrombolysis in Myocardial Infarction (TIMI) major bleeding, minor bleeding, and bleeding requiring medical attention (BRMA). TIMI major bleeding is defined as any symptomatic intracranial hemorrhage, clinically overt signs of hemorrhage (including imaging) associated with a drop in hemoglobin of greater than or equal to (&gt;=) 5 grams per deciliter (g/dL) (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of &gt;=15 percent (%)). TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to less than (&lt;) 5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to &lt;15 percent). A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event.</description>
        <time_frame>Up to Month 12</time_frame>
        <population>The safety analysis set is defined as all randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban 15 mg</title>
            <description>Participants received rivaroxaban 15 milligram (mg) or 10 mg (for participants with moderate renal impairment [creatinine clearance (CrCl): 30 to less than (&lt;) 50 milliliter per minute (mL/min)]) once daily plus background therapy with clopidogrel 75 mg once daily or alternate P2Y12 inhibitor (prasugrel 10 mg per day or ticagrelor 90 mg twice daily) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)</title>
            <description>Participants received rivaroxaban 2.5 mg twice daily plus background dual antiplatelet therapy (DAPT) with low-dose acetylsalicylic acid (ASA) 75 to 100 mg per day and clopidogrel 75 mg once daily (or alternate P2Y12 inhibitor [prasugrel or ticagrelor]) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive rivaroxaban 15 mg or 10 mg (for participants with moderate renal impairment) once daily plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Vitamin K Antagonist (VKA)</title>
            <description>Participants received dose adjusted (to a target of international normalized ratio [INR] 2.0 to 3.0 [or target INR 2.0 to 2.5]) vitamin K antagonist (VKA) [example warfarin, acenocoumarol; assigned by the investigator according to approved formulations) once daily plus background DAPT (clopidogrel 75 mg [or alternate P2Y12 inhibitor (prasugrel or ticagrelor)] plus low-dose ASA [75 to 100 mg] daily) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive dose-adjusted VKA plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinically Significant Bleeding</title>
          <description>Clinically significant bleeding is a composite of Thrombolysis in Myocardial Infarction (TIMI) major bleeding, minor bleeding, and bleeding requiring medical attention (BRMA). TIMI major bleeding is defined as any symptomatic intracranial hemorrhage, clinically overt signs of hemorrhage (including imaging) associated with a drop in hemoglobin of greater than or equal to (&gt;=) 5 grams per deciliter (g/dL) (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of &gt;=15 percent (%)). TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to less than (&lt;) 5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to &lt;15 percent). A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event.</description>
          <population>The safety analysis set is defined as all randomized participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="696"/>
                <count group_id="O2" value="706"/>
                <count group_id="O3" value="697"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7"/>
                    <measurement group_id="O2" value="16.6"/>
                    <measurement group_id="O3" value="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding</title>
        <description>TIMI major bleeding is defined as any symptomatic intracranial hemorrhage, Clinically overt signs of hemorrhage (including imaging) associated with a drop in hemoglobin of &gt;= 5 g/dL (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of &gt;=15 percent).</description>
        <time_frame>Up to Month 12 and end of DAPT-Month 1, 6 and 12</time_frame>
        <population>The safety analysis set is defined as all randomized participants who received at least 1 dose of study drug. Here, 'n' signifies number of participants analyzed at specific time-point in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban 15 mg</title>
            <description>Participants received rivaroxaban 15 milligram (mg) or 10 mg (for participants with moderate renal impairment [creatinine clearance (CrCl): 30 to less than (&lt;) 50 milliliter per minute (mL/min)]) once daily plus background therapy with clopidogrel 75 mg once daily or alternate P2Y12 inhibitor (prasugrel 10 mg per day or ticagrelor 90 mg twice daily) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)</title>
            <description>Participants received rivaroxaban 2.5 mg twice daily plus background dual antiplatelet therapy (DAPT) with low-dose acetylsalicylic acid (ASA) 75 to 100 mg per day and clopidogrel 75 mg once daily (or alternate P2Y12 inhibitor [prasugrel or ticagrelor]) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive rivaroxaban 15 mg or 10 mg (for participants with moderate renal impairment) once daily plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Vitamin K Antagonist (VKA)</title>
            <description>Participants received dose adjusted (to a target of international normalized ratio [INR] 2.0 to 3.0 [or target INR 2.0 to 2.5]) vitamin K antagonist (VKA) [example warfarin, acenocoumarol; assigned by the investigator according to approved formulations) once daily plus background DAPT (clopidogrel 75 mg [or alternate P2Y12 inhibitor (prasugrel or ticagrelor)] plus low-dose ASA [75 to 100 mg] daily) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive dose-adjusted VKA plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding</title>
          <description>TIMI major bleeding is defined as any symptomatic intracranial hemorrhage, Clinically overt signs of hemorrhage (including imaging) associated with a drop in hemoglobin of &gt;= 5 g/dL (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of &gt;=15 percent).</description>
          <population>The safety analysis set is defined as all randomized participants who received at least 1 dose of study drug. Here, 'n' signifies number of participants analyzed at specific time-point in this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="696"/>
                <count group_id="O2" value="706"/>
                <count group_id="O3" value="697"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to Month 12 (n= 696, 706, 697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-1 Month (n= 0, 108,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-1 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-6 Month (n= 0, 248,243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-6 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="2.8"/>
                    <measurement group_id="O3" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-12 Month (n= 0, 350,341)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-12 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.234</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.114</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Minor Bleeding</title>
        <description>TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to &lt;5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to &lt;15 percent).</description>
        <time_frame>Up to Month 12 and end of DAPT-Month 1, 6 and 12</time_frame>
        <population>The safety analysis set is defined as all randomized participants who received at least 1 dose of study drug. Here 'n' signifies number of participants analyzed at specific time-point in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban 15 mg</title>
            <description>Participants received rivaroxaban 15 milligram (mg) or 10 mg (for participants with moderate renal impairment [creatinine clearance (CrCl): 30 to less than (&lt;) 50 milliliter per minute (mL/min)]) once daily plus background therapy with clopidogrel 75 mg once daily or alternate P2Y12 inhibitor (prasugrel 10 mg per day or ticagrelor 90 mg twice daily) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)</title>
            <description>Participants received rivaroxaban 2.5 mg twice daily plus background dual antiplatelet therapy (DAPT) with low-dose acetylsalicylic acid (ASA) 75 to 100 mg per day and clopidogrel 75 mg once daily (or alternate P2Y12 inhibitor [prasugrel or ticagrelor]) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive rivaroxaban 15 mg or 10 mg (for participants with moderate renal impairment) once daily plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Vitamin K Antagonist (VKA)</title>
            <description>Participants received dose adjusted (to a target of international normalized ratio [INR] 2.0 to 3.0 [or target INR 2.0 to 2.5]) vitamin K antagonist (VKA) [example warfarin, acenocoumarol; assigned by the investigator according to approved formulations) once daily plus background DAPT (clopidogrel 75 mg [or alternate P2Y12 inhibitor (prasugrel or ticagrelor)] plus low-dose ASA [75 to 100 mg] daily) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive dose-adjusted VKA plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Minor Bleeding</title>
          <description>TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to &lt;5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to &lt;15 percent).</description>
          <population>The safety analysis set is defined as all randomized participants who received at least 1 dose of study drug. Here 'n' signifies number of participants analyzed at specific time-point in this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="696"/>
                <count group_id="O2" value="706"/>
                <count group_id="O3" value="697"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to Month 12 (n= 696, 706, 697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-1 Month (n= 0, 108, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-1 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-6 Month (n= 0, 248, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-6 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-12 Month (n= 0, 350, 341)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-12 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="1.4"/>
                    <measurement group_id="O3" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.144</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.134</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Bleeding Requiring Medical Attention (BRMA)</title>
        <description>A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event.</description>
        <time_frame>Up to Month 12 and end of DAPT-Month 1, 6 and 12</time_frame>
        <population>The safety analysis set is defined as all randomized participants who received at least 1 dose of study drug. Here 'n' signifies number of participants analyzed at specific time-point in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban 15 mg</title>
            <description>Participants received rivaroxaban 15 milligram (mg) or 10 mg (for participants with moderate renal impairment [creatinine clearance (CrCl): 30 to less than (&lt;) 50 milliliter per minute (mL/min)]) once daily plus background therapy with clopidogrel 75 mg once daily or alternate P2Y12 inhibitor (prasugrel 10 mg per day or ticagrelor 90 mg twice daily) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)</title>
            <description>Participants received rivaroxaban 2.5 mg twice daily plus background dual antiplatelet therapy (DAPT) with low-dose acetylsalicylic acid (ASA) 75 to 100 mg per day and clopidogrel 75 mg once daily (or alternate P2Y12 inhibitor [prasugrel or ticagrelor]) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive rivaroxaban 15 mg or 10 mg (for participants with moderate renal impairment) once daily plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Vitamin K Antagonist (VKA)</title>
            <description>Participants received dose adjusted (to a target of international normalized ratio [INR] 2.0 to 3.0 [or target INR 2.0 to 2.5]) vitamin K antagonist (VKA) [example warfarin, acenocoumarol; assigned by the investigator according to approved formulations) once daily plus background DAPT (clopidogrel 75 mg [or alternate P2Y12 inhibitor (prasugrel or ticagrelor)] plus low-dose ASA [75 to 100 mg] daily) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive dose-adjusted VKA plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Bleeding Requiring Medical Attention (BRMA)</title>
          <description>A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event.</description>
          <population>The safety analysis set is defined as all randomized participants who received at least 1 dose of study drug. Here 'n' signifies number of participants analyzed at specific time-point in this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="696"/>
                <count group_id="O2" value="706"/>
                <count group_id="O3" value="697"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to Month 12 (n= 696, 706, 697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4"/>
                    <measurement group_id="O2" value="14.4"/>
                    <measurement group_id="O3" value="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-1 Month (n= 0, 108, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-1 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-6 Month (n= 0, 248, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-6 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="12.9"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-12 Month (n= 0, 350, 341)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-12 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="14.9"/>
                    <measurement group_id="O3" value="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Composite of Adverse Cardiovascular Events (Cardiovascular Death, Myocardial Infarction (MI) and Stroke)</title>
        <description>Percentage of participants who experienced adverse cardiovascular events (cardiovascular death, myocardial Infarction (MI) and stroke) collectively, were assessed.</description>
        <time_frame>Up to Month 12 and end of DAPT-Month 1, 6 and 12</time_frame>
        <population>The safety analysis set is defined as all randomized participants who received at least 1 dose of study drug. Here 'N' signifies number of participants who were evaluable for this outcome measure, 'n' signifies number of participants analyzed at specific time-point in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban 15 mg</title>
            <description>Participants received rivaroxaban 15 milligram (mg) or 10 mg (for participants with moderate renal impairment [creatinine clearance (CrCl): 30 to less than (&lt;) 50 milliliter per minute (mL/min)]) once daily plus background therapy with clopidogrel 75 mg once daily or alternate P2Y12 inhibitor (prasugrel 10 mg per day or ticagrelor 90 mg twice daily) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)</title>
            <description>Participants received rivaroxaban 2.5 mg twice daily plus background dual antiplatelet therapy (DAPT) with low-dose acetylsalicylic acid (ASA) 75 to 100 mg per day and clopidogrel 75 mg once daily (or alternate P2Y12 inhibitor [prasugrel or ticagrelor]) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive rivaroxaban 15 mg or 10 mg (for participants with moderate renal impairment) once daily plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Vitamin K Antagonist (VKA)</title>
            <description>Participants received dose adjusted (to a target of international normalized ratio [INR] 2.0 to 3.0 [or target INR 2.0 to 2.5]) vitamin K antagonist (VKA) [example warfarin, acenocoumarol; assigned by the investigator according to approved formulations) once daily plus background DAPT (clopidogrel 75 mg [or alternate P2Y12 inhibitor (prasugrel or ticagrelor)] plus low-dose ASA [75 to 100 mg] daily) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive dose-adjusted VKA plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Composite of Adverse Cardiovascular Events (Cardiovascular Death, Myocardial Infarction (MI) and Stroke)</title>
          <description>Percentage of participants who experienced adverse cardiovascular events (cardiovascular death, myocardial Infarction (MI) and stroke) collectively, were assessed.</description>
          <population>The safety analysis set is defined as all randomized participants who received at least 1 dose of study drug. Here 'N' signifies number of participants who were evaluable for this outcome measure, 'n' signifies number of participants analyzed at specific time-point in this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="694"/>
                <count group_id="O2" value="704"/>
                <count group_id="O3" value="695"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to Month 12 (n= 694, 704, 695)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="5.1"/>
                    <measurement group_id="O3" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-1 Month (n= 0, 108, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-1 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="5.6"/>
                    <measurement group_id="O3" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-6 Month (n= 0, 248, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-6 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="6.5"/>
                    <measurement group_id="O3" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-12 Month (n= 0, 348, 340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-12 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.765</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Cardiovascular Death</title>
        <description>The percentage of participants with the first occurrence of cardiovascular death were evaluated.</description>
        <time_frame>Up to Month 12 and end of DAPT-Month 1, 6 and 12</time_frame>
        <population>The safety analysis set is defined as all randomized participants who received at least 1 dose of study drug. Here 'N' signifies number of participants who were evaluable for this outcome measure, 'n' signifies number of participants analyzed at specific time-point in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban 15 mg</title>
            <description>Participants received rivaroxaban 15 milligram (mg) or 10 mg (for participants with moderate renal impairment [creatinine clearance (CrCl): 30 to less than (&lt;) 50 milliliter per minute (mL/min)]) once daily plus background therapy with clopidogrel 75 mg once daily or alternate P2Y12 inhibitor (prasugrel 10 mg per day or ticagrelor 90 mg twice daily) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)</title>
            <description>Participants received rivaroxaban 2.5 mg twice daily plus background dual antiplatelet therapy (DAPT) with low-dose acetylsalicylic acid (ASA) 75 to 100 mg per day and clopidogrel 75 mg once daily (or alternate P2Y12 inhibitor [prasugrel or ticagrelor]) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive rivaroxaban 15 mg or 10 mg (for participants with moderate renal impairment) once daily plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Vitamin K Antagonist (VKA)</title>
            <description>Participants received dose adjusted (to a target of international normalized ratio [INR] 2.0 to 3.0 [or target INR 2.0 to 2.5]) vitamin K antagonist (VKA) [example warfarin, acenocoumarol; assigned by the investigator according to approved formulations) once daily plus background DAPT (clopidogrel 75 mg [or alternate P2Y12 inhibitor (prasugrel or ticagrelor)] plus low-dose ASA [75 to 100 mg] daily) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive dose-adjusted VKA plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Cardiovascular Death</title>
          <description>The percentage of participants with the first occurrence of cardiovascular death were evaluated.</description>
          <population>The safety analysis set is defined as all randomized participants who received at least 1 dose of study drug. Here 'N' signifies number of participants who were evaluable for this outcome measure, 'n' signifies number of participants analyzed at specific time-point in this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="694"/>
                <count group_id="O2" value="704"/>
                <count group_id="O3" value="695"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to Month 12 (n= 694, 704, 695)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-1 Month (n= 0, 108, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-1 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="1.9"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-6 Month (n= 0, 248, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-6 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-12 Month (n= 0, 348, 340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-12 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.523</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.664</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>2.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Myocardial Infarction</title>
        <description>The percentage of participants with the first occurrence of Myocardial Infarction were evaluated.</description>
        <time_frame>Up to Month 12 and end of DAPT-Month 1, 6 and 12</time_frame>
        <population>The safety analysis set is defined as all randomized participants who received at least 1 dose of study drug. Here 'N' signifies number of participants who were evaluable for this outcome measure, 'n' signifies number of participants analyzed at specific time-point in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban 15 mg</title>
            <description>Participants received rivaroxaban 15 milligram (mg) or 10 mg (for participants with moderate renal impairment [creatinine clearance (CrCl): 30 to less than (&lt;) 50 milliliter per minute (mL/min)]) once daily plus background therapy with clopidogrel 75 mg once daily or alternate P2Y12 inhibitor (prasugrel 10 mg per day or ticagrelor 90 mg twice daily) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)</title>
            <description>Participants received rivaroxaban 2.5 mg twice daily plus background dual antiplatelet therapy (DAPT) with low-dose acetylsalicylic acid (ASA) 75 to 100 mg per day and clopidogrel 75 mg once daily (or alternate P2Y12 inhibitor [prasugrel or ticagrelor]) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive rivaroxaban 15 mg or 10 mg (for participants with moderate renal impairment) once daily plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Vitamin K Antagonist (VKA)</title>
            <description>Participants received dose adjusted (to a target of international normalized ratio [INR] 2.0 to 3.0 [or target INR 2.0 to 2.5]) vitamin K antagonist (VKA) [example warfarin, acenocoumarol; assigned by the investigator according to approved formulations) once daily plus background DAPT (clopidogrel 75 mg [or alternate P2Y12 inhibitor (prasugrel or ticagrelor)] plus low-dose ASA [75 to 100 mg] daily) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive dose-adjusted VKA plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Myocardial Infarction</title>
          <description>The percentage of participants with the first occurrence of Myocardial Infarction were evaluated.</description>
          <population>The safety analysis set is defined as all randomized participants who received at least 1 dose of study drug. Here 'N' signifies number of participants who were evaluable for this outcome measure, 'n' signifies number of participants analyzed at specific time-point in this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="694"/>
                <count group_id="O2" value="704"/>
                <count group_id="O3" value="695"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to Month 12 (n= 694, 704, 695)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-1 Month (n= 0, 108, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-1 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="2.8"/>
                    <measurement group_id="O3" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-6 Month (n= 0, 248, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-6 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="2.8"/>
                    <measurement group_id="O3" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-12 Month (n= 0, 348, 340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-12 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.625</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.374</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Stroke</title>
        <description>The percentage of participants with the first occurrence of Stroke were evaluated.</description>
        <time_frame>Up to Month 12 and end of DAPT-Month 1, 6 and 12</time_frame>
        <population>The safety analysis set is defined as all randomized participants who received at least 1 dose of study drug. Here 'N' signifies number of participants who were evaluable for this outcome measure, 'n' signifies number of participants analyzed at specific time-point in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban 15 mg</title>
            <description>Participants received rivaroxaban 15 milligram (mg) or 10 mg (for participants with moderate renal impairment [creatinine clearance (CrCl): 30 to less than (&lt;) 50 milliliter per minute (mL/min)]) once daily plus background therapy with clopidogrel 75 mg once daily or alternate P2Y12 inhibitor (prasugrel 10 mg per day or ticagrelor 90 mg twice daily) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)</title>
            <description>Participants received rivaroxaban 2.5 mg twice daily plus background dual antiplatelet therapy (DAPT) with low-dose acetylsalicylic acid (ASA) 75 to 100 mg per day and clopidogrel 75 mg once daily (or alternate P2Y12 inhibitor [prasugrel or ticagrelor]) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive rivaroxaban 15 mg or 10 mg (for participants with moderate renal impairment) once daily plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Vitamin K Antagonist (VKA)</title>
            <description>Participants received dose adjusted (to a target of international normalized ratio [INR] 2.0 to 3.0 [or target INR 2.0 to 2.5]) vitamin K antagonist (VKA) [example warfarin, acenocoumarol; assigned by the investigator according to approved formulations) once daily plus background DAPT (clopidogrel 75 mg [or alternate P2Y12 inhibitor (prasugrel or ticagrelor)] plus low-dose ASA [75 to 100 mg] daily) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive dose-adjusted VKA plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Stroke</title>
          <description>The percentage of participants with the first occurrence of Stroke were evaluated.</description>
          <population>The safety analysis set is defined as all randomized participants who received at least 1 dose of study drug. Here 'N' signifies number of participants who were evaluable for this outcome measure, 'n' signifies number of participants analyzed at specific time-point in this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="694"/>
                <count group_id="O2" value="704"/>
                <count group_id="O3" value="695"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to Month 12 (n= 694, 704, 695)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-1 Month (n= 0, 108, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-1 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="1.9"/>
                    <measurement group_id="O3" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-6 Month (n= 0, 248, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-6 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-12 Month (n= 0, 348, 340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-12 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="0.6"/>
                    <measurement group_id="O3" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.891</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>2.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>3.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Stent Thrombosis</title>
        <description>The percentage of participants with the first occurrence of stent thrombosis were evaluated.</description>
        <time_frame>Up to Month 12 and end of DAPT-Month 1, 6 and 12</time_frame>
        <population>The safety analysis set is defined as all randomized participants who received at least 1 dose of study drug. Here 'N' signifies number of participants who were evaluable for this outcome measure, 'n' signifies number of participants analyzed at specific time-point in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban 15 mg</title>
            <description>Participants received rivaroxaban 15 milligram (mg) or 10 mg (for participants with moderate renal impairment [creatinine clearance (CrCl): 30 to less than (&lt;) 50 milliliter per minute (mL/min)]) once daily plus background therapy with clopidogrel 75 mg once daily or alternate P2Y12 inhibitor (prasugrel 10 mg per day or ticagrelor 90 mg twice daily) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)</title>
            <description>Participants received rivaroxaban 2.5 mg twice daily plus background dual antiplatelet therapy (DAPT) with low-dose acetylsalicylic acid (ASA) 75 to 100 mg per day and clopidogrel 75 mg once daily (or alternate P2Y12 inhibitor [prasugrel or ticagrelor]) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive rivaroxaban 15 mg or 10 mg (for participants with moderate renal impairment) once daily plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Vitamin K Antagonist (VKA)</title>
            <description>Participants received dose adjusted (to a target of international normalized ratio [INR] 2.0 to 3.0 [or target INR 2.0 to 2.5]) vitamin K antagonist (VKA) [example warfarin, acenocoumarol; assigned by the investigator according to approved formulations) once daily plus background DAPT (clopidogrel 75 mg [or alternate P2Y12 inhibitor (prasugrel or ticagrelor)] plus low-dose ASA [75 to 100 mg] daily) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive dose-adjusted VKA plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Stent Thrombosis</title>
          <description>The percentage of participants with the first occurrence of stent thrombosis were evaluated.</description>
          <population>The safety analysis set is defined as all randomized participants who received at least 1 dose of study drug. Here 'N' signifies number of participants who were evaluable for this outcome measure, 'n' signifies number of participants analyzed at specific time-point in this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="694"/>
                <count group_id="O2" value="704"/>
                <count group_id="O3" value="695"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Up to Month 12 (n= 694, 704, 695)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-1 Month (n= 0, 108, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-1 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="1.9"/>
                    <measurement group_id="O3" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-6 Month (n= 0, 248, 243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-6 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="1.6"/>
                    <measurement group_id="O3" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of DAPT-12 Month (n= 0, 348, 340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Analysis at end of DAPT-12 month conducted only in participants who received DAPT as part of therapy.</measurement>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>4.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.574</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>5.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Upto 12 months</time_frame>
      <desc>The Safety Analysis Set is defined as all randomized participants who received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Rivaroxaban 15 mg</title>
          <description>Participants received rivaroxaban 15 milligram (mg) or 10 mg (for participants with moderate renal impairment [creatinine clearance (CrCl): 30 to less than (&lt;) 50 milliliter per minute (mL/min)]) once daily plus background therapy with clopidogrel 75 mg once daily or alternate P2Y12 inhibitor (prasugrel 10 mg per day or ticagrelor 90 mg twice daily) for 12 months.</description>
        </group>
        <group group_id="E2">
          <title>Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)</title>
          <description>Participants received rivaroxaban 2.5 mg twice daily plus background dual antiplatelet therapy (DAPT) with low-dose acetylsalicylic acid (ASA) 75 to 100 mg per day and clopidogrel 75 mg once daily (or alternate P2Y12 inhibitor [prasugrel or ticagrelor]) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive rivaroxaban 15 mg or 10 mg (for participants with moderate renal impairment) once daily plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
        </group>
        <group group_id="E3">
          <title>Vitamin K Antagonist (VKA)</title>
          <description>Participants received dose adjusted (to a target of international normalized ratio [INR] 2.0 to 3.0 [or target INR 2.0 to 2.5]) vitamin K antagonist (VKA) [example warfarin, acenocoumarol; assigned by the investigator according to approved formulations) once daily plus background DAPT (clopidogrel 75 mg [or alternate P2Y12 inhibitor (prasugrel or ticagrelor)] plus low-dose ASA [75 to 100 mg] daily) for an intended DAPT duration of 1, 6, or 12 months. Only participants with an intended DAPT duration of 1 or 6-month transitioned to receive dose-adjusted VKA plus background single antiplatelet therapy with low-dose ASA for the rest of the period up to Month 12.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="237" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="225" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="271" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hypergammaglobulinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hypochromic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Microcytic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Atrial Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Atrial Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiac Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Chronic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiac Pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiovascular Disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Coronary Artery Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dressler's Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ischaemic Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Left Ventricular Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Left Ventricular Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pericardial Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Sinus Node Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Tachycardia Induced Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ventricular Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ventricular Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness Neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Age-Related Macular Degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Eye Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Vitreous Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Acute Abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Anal Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Anal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Barrett's Oesophagus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Change of Bowel Habit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Colitis Microscopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Crohn's Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastric Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastric Mucosa Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastritis Erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastritis Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hiatus Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Impaired Gastric Emptying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Intestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Intestinal Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Intra-Abdominal Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lower Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Mouth Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pancreatitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Tongue Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter Site Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Device Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Drug Intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Drug Resistance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Drug Withdrawal Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gait Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Medical Device Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Sudden Cardiac Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ulcer Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Vascular Stent Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Vascular Stent Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Vascular Stent Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile Duct Stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cholecystitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hepatic Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hepatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hepatitis Toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hepatocellular Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal Wall Abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Abscess Limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bacterial Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bronchitis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Encephalitis Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haematoma Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Infected Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Infective Exacerbation of Chronic Obstructive Airways Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Intervertebral Discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Liver Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Localised Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Scrotal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Coronary Artery Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Craniocerebral Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Incisional Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Muscle Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pneumothorax Traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Post Procedural Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Post Procedural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Post Procedural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pubis Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Subdural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Toxicity to Various Agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Traumatic Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Traumatic Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Vascular Pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Wound Dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy Prostate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiac Stress Test</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ejection Fraction Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Electrocardiogram Ambulatory Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>International Normalised Ratio Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lipids Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Diabetic Metabolic Decompensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Metabolic Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Type 2 Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gouty Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Joint Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lumbar Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rheumatic Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Spinal Column Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Spinal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Spinal Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Spinal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adrenal Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ameloblastoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bladder Cancer Recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bladder Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bowen's Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Brain Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Breast Cancer Stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bronchial Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Colon Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Colorectal Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Diffuse Large B-Cell Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gallbladder Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Stromal Tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hepatocellular Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Metastases to Liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ovarian Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pituitary Tumour Benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rectal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rectal Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Renal Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Small Cell Lung Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cerebral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dizziness Postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hemianopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Intercostal Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Intracranial Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lacunar Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Parkinson's Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Tension Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Viith Nerve Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Anxiety Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bladder Tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Calculus Urethral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Calculus Urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haemorrhage Urinary Tract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Prerenal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Renal Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Urethral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Urethral Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bronchitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bronchopneumopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dyspnoea at Rest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Interstitial Lung Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lung Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pulmonary Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pulmonary Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pulmonary Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Sleep Apnoea Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Neurodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Skin Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Aortic Valve Replacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiac Ablation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiac Pacemaker Insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiac Resynchronisation Therapy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardioversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Coronary Arterial Stent Insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Coronary Artery Bypass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ileostomy Closure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Implantable Defibrillator Insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Knee Arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Mitral Valve Repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Percutaneous Coronary Intervention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Renal Sympathetic Nerve Ablation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Tooth Extraction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Aortic Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Arterial Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Arteriovenous Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Circulatory Collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Extremity Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Femoral Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Intermittent Claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Malignant Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Peripheral Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Peripheral Vascular Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Shock Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Venous Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Venous Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA Version 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="174" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="210" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="234" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gingival Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Subcutaneous Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="706"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>First the stratification to either 1, 6 or 12 months of DAPT was based upon clinician choice and was not randomized. Secondly there was not sufficient power to definitively assess efficacy due to the modest number of adverse CV events.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Director Clinical Development</name_or_title>
      <organization>Janssen Scientific Affairs, LLC</organization>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

